TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Frequency and severity of solicited local and systemic adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate (SCR) of SARS-CoV-2-specific neutralising antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfaction With MBTA Tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brain function states
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the blood carbon stable isotope ratio (13C/12C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the hair carbon stable isotope ratio (13C/12C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGFR at 24 weeks posttransplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Microbiologically confirmed melioidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in weeknight sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: dietary phenylalanine tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint position sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate in Investigator's Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: moderate or severe prosthetic valve regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: permanent pacemaker implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the caregiver's competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of participants randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage of participants completing the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of participants taking at least 80% of pills
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physeal dysplasia occurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Flu Shot Receipt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients who reach neutrophil engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rate of treatment-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Marginal integrity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GBS disability score of 2 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Knee injury and osteoarthritis outcome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythropoetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diuresis change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity of patients' use of the digital therapeutic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in shoulder Range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in shoulder functional activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in scapular mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Prolapse and Incontinence Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Generalized Anxiety Disorder-7 (Gad-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire-8 (Phq-8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 28-days Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Infusion Related Reactions, Hypersensitivity Reactions and Any Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with ecchymosis developed
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac Efficiency after acute dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Efficiency after chronic dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Usage Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reaction Rate Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity proprioception measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the BEWE Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shiff Air Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BoP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average FMS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of BPH symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate of HBOT as complete response or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of aGVHD when HBOT was administrated as prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shanghai Elbow Dysfunction Score (SHEDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of retaining
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the intervention to patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in planned management strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peripheral oxygen saturation level (SpO2) 6 hours after tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peripheral oxygen saturation level (SpO2) 24 hours after tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak expiratory flow (PEF) 48 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The volume of atelectasis on chest computed tomography 36-48 hours after tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart failure death or hospitalisation for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Burden of non-sustained VT
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic complete response rate (pCR Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Prescribed Mineralocorticoid Receptor Antagonists (MRA)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nausea-vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate in lowering IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of hepatitis D infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: % of subjects satisfied with treatments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intercultural Sensitivity Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Penetration-aspiration score (PAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in horizontal bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in HER-1 receptor tyrosine kinases protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in HER-2 receptor tyrosine kinases protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in HER-3 receptor tyrosine kinases protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in HER-4 receptor tyrosine kinases protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: area under the plasma concentration time curve (AUC)0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary Intake of Ultra-Processed and Minimally-Processed Foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of the decision aid tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clarity of the decision aid tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the decision aid tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insulin secretion index (Φ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Validation of nanoparticles releasing FGFBP1 inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRIME-O Video Coding Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood Archaea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Steady-state plasma glucose at euinsulinemia (E-SSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steady-state plasma glucose at hyperinsulinemia (H-SSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Validated Cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite outcome of all major congenital malformations (MCMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Much Improved or Very Much Improved
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QoL): EQ-5D-5L index value
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QoL): EQ-Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of moderate dementia patients with normal range of blood parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with improved Mini mental status examination, mini cog and AD8
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with improved Glial Fibrillary Acid Protein (GFAP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of peripheral blood CD45+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Postoperative Sleep Disorders
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of Psoriatic Arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adherence to azathioprine therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood oxygen pressure (PaO2) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Occlusion Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Craving of sexual addiction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective emotional response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective emotional response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achievement rate of the target serum phosphorus level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Children's Eating Behavior Questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of foods consumed by participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Child Food Neophobia score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade-A healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new-onset diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stem Subsidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with unmedicated DIOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Conversion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Adverse Events (AEs) by body system
Endpoint domain: Adverse events/effects
Primary endpoint: Total Radioactivity Recovery (fet1-t2) in Urine and Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) of BGB-16673
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of BGB-16673
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute gastrointestinal (GI) toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mental Health Status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delta MSA (cross Sectional Area post-PCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time taken for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Spontaneous Bacterial Peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic pain intensity on average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic pain intensity at its worst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Father's Impact on Breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Partner Support in Early Postpartum
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with changes in clinically significant vital sign from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burn depth assessment accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient thirty level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of CD19-CD22-CAR T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Vital Sign Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom relief assessed by the GERD-Q score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desensitization to the culprit food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCV/EMG (CMAP, latency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of developmental delays
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Blood pressure response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective weight of saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inventory of Interpersonal Problems-32 (IIP-32)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HPGD Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Short echo T2*
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STAR-Sonographic Thigh Adjustment Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ct-DNA clearance rate after the end of adjuvant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysis symptoms index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection rates of AF during ECG monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Richmond agitation sedation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta Bishop score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of mirdametinib
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase 2 dose (RP2D) of mirdametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary anti-tumor activity of mirdametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Collection and analysis of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in body temperature measurement from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in blood pressure measurement from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Obstetric Anal Sphincter Injuries (OASIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: program coverage rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: screening participation rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: high-risk rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inpatient death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment-emergent adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor cell necrosis rate (TCNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visits to a neurologist
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Use of physical therapy services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient's Activation Measure (PAM-13®, Insignia Health)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: International Physical Activity Questionnaire- IPAQ-SHORT
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: GMT of neutralizing antibodies to Delta variant on D28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of neutralizing antibodies to Omicron variant on D28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and severity of solicited AEs from D0 to D7 after study vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of computer software in predicting soft tissue profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of the Wechsler Memory Scale - Third Edition (WMS-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Stroop Color-Word Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Latency in Horizontal saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Main velocity in Horizontal saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes